{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:42:10Z","timestamp":1777668130405,"version":"3.51.4"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA217378"],"award-info":[{"award-number":["U54-CA217378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008982","name":"Ministry of Technology & Research | National Science Foundation","doi-asserted-by":"publisher","award":["DMS1763272"],"award-info":[{"award-number":["DMS1763272"]}],"id":[{"id":"10.13039\/501100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000893","name":"Simons Foundation","doi-asserted-by":"publisher","award":["594598"],"award-info":[{"award-number":["594598"]}],"id":[{"id":"10.13039\/100000893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-16-181-57"],"award-info":[{"award-number":["IRG-16-181-57"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During progression from carcinoma in situ to an invasive tumor, the immune system is engaged in complex sets of interactions with various tumor cells. Tumor cell plasticity alters disease trajectories via epithelial-to-mesenchymal transition (EMT). Several of the same pathways that regulate EMT are involved in tumor-immune interactions, yet little is known about the mechanisms and consequences of crosstalk between these regulatory processes. Here we introduce a multiscale evolutionary model to describe tumor-immune-EMT interactions and their impact on epithelial cancer progression from in situ to invasive disease. Through simulation of patient cohorts in silico, the model predicts that a controllable region maximizes invasion-free survival. This controllable region depends on properties of the mesenchymal tumor cell phenotype: its growth rate and its immune-evasiveness. In light of the model predictions, we analyze EMT-inflammation-associated data from The Cancer Genome Atlas, and find that association with EMT worsens invasion-free survival probabilities. This result supports the predictions of the model, and leads to the identification of genes that influence outcomes in bladder and uterine cancer, including FGF pathway members. These results suggest new means to delay disease progression, and demonstrate the importance of studying cancer-immune interactions in light of EMT.<\/jats:p>","DOI":"10.1038\/s42003-021-02499-y","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T10:14:09Z","timestamp":1629281649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Modeling the effects of EMT-immune dynamics on carcinoma disease progression"],"prefix":"10.1038","volume":"4","author":[{"given":"Daniel R.","family":"Bergman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew K.","family":"Karikomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0689-7907","authenticated-orcid":false,"given":"Adam L.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"2499_CR1","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillek\u00e5s","year":"2019","unstructured":"Dillek\u00e5s, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 8, 5574\u20135576 (2019).","journal-title":"Cancer Med."},{"key":"2499_CR2","doi-asserted-by":"crossref","unstructured":"Ryan, B. M. & Faupel-Badger, J. M. The hallmarks of premalignant conditions: a molecular basis for cancer prevention. In Seminars in oncology, Vol. 43, pp. 22\u201335 (Elsevier, 2016).","DOI":"10.1053\/j.seminoncol.2015.09.007"},{"key":"2499_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE De Visser","year":"2006","unstructured":"De Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR4","doi-asserted-by":"publisher","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","volume":"23","author":"OJ Finn","year":"2012","unstructured":"Finn, O. J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23, viii6\u2013viii9 (2012).","journal-title":"Ann. Oncol."},{"key":"2499_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. Pd-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"2499_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cytogfr.2009.11.002","volume":"21","author":"B Ruffell","year":"2010","unstructured":"Ruffell, B., DeNardo, D. G., Affara, N. I. & Coussens, L. M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 21, 3\u201310 (2010).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2499_CR7","doi-asserted-by":"publisher","first-page":"21635","DOI":"10.1073\/pnas.1016814108","volume":"107","author":"B Hu","year":"2010","unstructured":"Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. 107, 21635\u201321640 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2499_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539\u2013545 (2001).","journal-title":"Lancet"},{"key":"2499_CR9","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/0008-5472.CAN-17-1662","volume":"77","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. Multiscale modeling of inflammation-induced tumorigenesis reveals competing oncogenic and oncoprotective roles for inflammation. Cancer Res. 77, 6429\u20136441 (2017).","journal-title":"Cancer Res."},{"key":"2499_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the t cell response. Nat. Rev. Immunol. 12, 269 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2499_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-cd19 car t cell therapy. Nat. Med. 25, 1 (2019).","journal-title":"Nat. Med."},{"key":"2499_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunityas roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"2499_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21\u201345 (2016).","journal-title":"Cell"},{"key":"2499_CR15","doi-asserted-by":"publisher","first-page":"31790","DOI":"10.18632\/oncotarget.25852","volume":"9","author":"Q Nie","year":"2018","unstructured":"Nie, Q. Stem cells: a window of opportunity in low-dimensional EMT space. Oncotarget 9, 31790\u201331791 (2018).","journal-title":"Oncotarget"},{"key":"2499_CR16","doi-asserted-by":"publisher","first-page":"021001","DOI":"10.1088\/1478-3975\/aaf928","volume":"16","author":"Y Sha","year":"2019","unstructured":"Sha, Y. et al. & Haensel, D. Intermediate cell states in epithelial-to-mesenchymal transition. Phys. Biol. 16, 021001 (2019).","journal-title":"Phys. Biol."},{"key":"2499_CR17","doi-asserted-by":"publisher","first-page":"e1004569","DOI":"10.1371\/journal.pcbi.1004569","volume":"11","author":"T Hong","year":"2015","unstructured":"Hong, T. et al. An ovol2-zeb1 mutual inhibitory circuit governs bidirectional and multi-step transition between epithelial and mesenchymal states. PLoS Comput. Biol. 11, e1004569 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"2499_CR18","doi-asserted-by":"publisher","first-page":"25161","DOI":"10.18632\/oncotarget.4629","volume":"6","author":"MK Jolly","year":"2015","unstructured":"Jolly, M. K. et al. Coupling the modules of EMT and stemness: a tunable \u2018stemness window\u2019 model. Oncotarget 6, 25161\u201325174 (2015).","journal-title":"Oncotarget"},{"key":"2499_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrg.2016.98","volume":"17","author":"N Moris","year":"2016","unstructured":"Moris, N., Pina, C. & Martinez Arias, A. Transition states and cell fate decisions in epigenetic landscapes. Nat. Rev. Genet. 17, 693\u2013703 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"2499_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coisb.2018.02.009","volume":"9","author":"AL MacLean","year":"2018","unstructured":"MacLean, A. L., Hong, T. & Nie, Q. Exploring intermediate cell states through the lens of single cells. Curr. Opin. Syst. Biol. 9, 32\u201341 (2018).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"2499_CR21","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3934\/dcdsb.2016047","volume":"21","author":"CH Ta","year":"2016","unstructured":"Ta, C. H., Nie, Q. & Hong, T. Controlling stochasticity in epithelial-mesenchymal transition through multiple intermediate cellular states. Discrete Continuous Dyn. Syst. Ser. B 21, 2275\u20132291 (2016).","journal-title":"Discrete Continuous Dyn. Syst. Ser. B"},{"key":"2499_CR22","first-page":"612","volume":"13","author":"C Rackauckas","year":"2018","unstructured":"Rackauckas, C., Schilling, T. F. & Nie, Q. Mean-independent noise control of cell fates via intermediate states. iScience 13, 612\u2013632 (2018).","journal-title":"iScience"},{"key":"2499_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fonc.2014.00367","volume":"4","author":"K Woods","year":"2014","unstructured":"Woods, K., Pasam, A., Jayachandran, A., Andrews, M. C. & Cebon, J. Effects of epithelial to mesenchymal transition on t cell targeting of melanoma cells. Front. Oncol. 4, 367 (2014).","journal-title":"Front. Oncol."},{"key":"2499_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/1878-0261.12093","volume":"11","author":"S Terry","year":"2017","unstructured":"Terry, S. et al. New insights into the role of emt in tumor immune escape. Mol. Oncol. 11, 824\u2013846 (2017).","journal-title":"Mol. Oncol."},{"key":"2499_CR25","doi-asserted-by":"publisher","first-page":"415 EP\u2013","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado, H., Olmeda, D. & Cano, A. Snail, zeb and bhlh factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415 EP\u2013 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.trecan.2018.10.010","volume":"5","author":"C Prunier","year":"2019","unstructured":"Prunier, C., Baker, D., tenDijke, P. & Ritsma, L. Tgf-\u03b2 family signaling pathways in cellular dormancy. Trends Cancer 5, 66\u201378 (2019).","journal-title":"Trends Cancer"},{"key":"2499_CR27","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1242\/dev.071209","volume":"139","author":"J Lim","year":"2012","unstructured":"Lim, J. & Thiery, J. P. Epithelial-mesenchymal transitions: insights from development. Development 139, 3471\u20133486 (2012).","journal-title":"Development"},{"key":"2499_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OTT.S172417","volume":"12","author":"C Shi","year":"2019","unstructured":"Shi, C. et al. Cd4+ cd25+ regulatory t cells promote hepatocellular carcinoma invasion via tgf-\u03b2 1-induced epithelial\u2013mesenchymal transition. OncoTargets Ther. 12, 279 (2019).","journal-title":"OncoTargets Ther."},{"key":"2499_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1006\/bulm.1998.0042","volume":"60","author":"ARA Anderson","year":"1998","unstructured":"Anderson, A. R. A. & Chaplain, M. A. J. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 60, 857\u2013899 (1998).","journal-title":"Bull. Math. Biol."},{"key":"2499_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1098\/rspb.1992.0071","volume":"248","author":"A Sherratt Jonathan","year":"1992","unstructured":"Sherratt Jonathan, A. & Nowak Martin, A. Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model. Proceeding. R. Soc. London. Ser. B Biol. Sci. 248, 261\u2013271 (1992).","journal-title":"Proceeding. R. Soc. London. Ser. B Biol. Sci."},{"key":"2499_CR31","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1158\/0008-5472.CAN-05-0564","volume":"65","author":"LGD Pillis","year":"2005","unstructured":"Pillis, L. G. D., Radunskaya, A. E. & Wiseman, C. L. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950\u20137958 (2005).","journal-title":"Cancer Res."},{"key":"2499_CR32","doi-asserted-by":"publisher","first-page":"e2002930","DOI":"10.1371\/journal.pbio.2002930","volume":"16","author":"E Kim","year":"2018","unstructured":"Kim, E., Kim, J.-Y., Smith, M. A., Haura, E. B. & Anderson, A. R. A. Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: an integrated approach to understanding targeted therapy. PLOS Biology 16, e2002930 (2018).","journal-title":"PLOS Biology"},{"key":"2499_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/0008-5472.CAN-13-0759","volume":"74","author":"J Gallaher","year":"2014","unstructured":"Gallaher, J., Babu, A., Plevritis, S. & Anderson, A. R. A. Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease. Cancer Res. 74, 426\u2013435 (2014).","journal-title":"Cancer Res."},{"key":"2499_CR34","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78, 2127\u20132139 (2018).","journal-title":"Cancer Res."},{"key":"2499_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mbs.2014.07.009","volume":"260","author":"G An","year":"2015","unstructured":"An, G. & Kulkarni, S. An agent-based modeling framework linking inflammation and cancer using evolutionary principles: Description of a generative hierarchy for the hallmarks of cancer and developing a bridge between mechanism and epidemiological data. Math. Biosci. 260, 16\u201324 (2015).","journal-title":"Math. Biosci."},{"key":"2499_CR36","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-15-3567","volume":"76","author":"R Serre","year":"2016","unstructured":"Serre, R. et al. Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy. Cancer Res. 76, 4931\u20134940 (2016).","journal-title":"Cancer Res."},{"key":"2499_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jtbi.2014.02.028","volume":"351","author":"Y Louzoun","year":"2014","unstructured":"Louzoun, Y., Xue, C., Lesinski, G. B. & Friedman, A. A mathematical model for pancreatic cancer growth and treatments. J. Theor. Biol 351, 74\u201382 (2014).","journal-title":"J. Theor. Biol"},{"key":"2499_CR38","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1158\/0008-5472.CAN-12-1916","volume":"73","author":"MA Briones-Orta","year":"2013","unstructured":"Briones-Orta, M. A. et al. Arkadia regulates tumor metastasis by modulation of the TGF-\u03b2 pathway. Cancer Res. 73, 1800\u20131810 (2013).","journal-title":"Cancer Res."},{"key":"2499_CR39","doi-asserted-by":"publisher","unstructured":"Lavi, O., Greene, J. M., Levy, D. & Gottesman, M. M. The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res., https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1768 (Oct 2013).","DOI":"10.1158\/0008-5472.CAN-13-1768"},{"key":"2499_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtbi.2014.11.017","volume":"367","author":"JM Greene","year":"2015","unstructured":"Greene, J. M. et al. Modeling intrinsic heterogeneity and growth of cancer cells. J. Theor. Biol. 367, 262\u2013277 (2015).","journal-title":"J. Theor. Biol."},{"key":"2499_CR41","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1158\/0008-5472.CAN-15-3232","volume":"76","author":"JM Greene","year":"2016","unstructured":"Greene, J. M., Levy, D., Herrada, S. P., Gottesman, M. M. & Lavi, O. Mathematical modeling reveals that changes to local cell density dynamically modulate baseline variations in cell growth and drug response. Cancer Res. 76, 2882\u20132890 (2016).","journal-title":"Cancer Res."},{"key":"2499_CR42","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s11538-017-0359-1","volume":"79","author":"H Cho","year":"2017","unstructured":"Cho, H. & Levy, D. Modeling the dynamics of heterogeneity of solid tumors in response to chemotherapy. Bull. Math. Biol. 79, 2986\u20133012 (2017).","journal-title":"Bull. Math. Biol."},{"key":"2499_CR43","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/0008-5472.CAN-17-0564","volume":"77","author":"S Benzekry","year":"2017","unstructured":"Benzekry, S., Lamont, C., Barbolosi, D., Hlatky, L. & Hahnfeldt, P. Mathematical modeling of tumor-tumor distant interactions supports a systemic control of tumor growth. Cancer Res. 77, 5183\u20135193 (2017).","journal-title":"Cancer Res."},{"key":"2499_CR44","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1158\/0008-5472.CAN-10-2834","volume":"71","author":"MR Owen","year":"2011","unstructured":"Owen, M. R. et al. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res. 71, 2826\u20132837 (2011).","journal-title":"Cancer Res."},{"key":"2499_CR45","doi-asserted-by":"publisher","unstructured":"West, J., You, L., Brown, J., Newton, P. K. & Anderson, A. R. Towards multi-drug adaptive therapy. bioRxiv 476507. https:\/\/doi.org\/10.1101\/476507v4 (2018).","DOI":"10.1101\/476507v4"},{"key":"2499_CR46","doi-asserted-by":"publisher","first-page":"e39950","DOI":"10.7554\/eLife.39950","volume":"8","author":"A Rozhok","year":"2019","unstructured":"Rozhok, A. & DeGregori, J. A generalized theory of age-dependent carcinogenesis. eLife 8, e39950 (2019).","journal-title":"eLife"},{"key":"2499_CR47","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. Tcgabiolinks: an r\/bioconductor package for integrative analysis of tcga data. Nucleic Acids Res. 44, e71\u2013e71 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2499_CR48","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated tcga pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416 (2018).","journal-title":"Cell"},{"key":"2499_CR49","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.copbio.2013.03.012","volume":"24","author":"PDW Kirk","year":"2013","unstructured":"Kirk, P. D. W., Thorne, T. & Stumpf, M. P. H. Model selection in systems and synthetic biology. Curr. Opin. Biotechnol. 24, 767\u2013774 (2013).","journal-title":"Curr. Opin. Biotechnol."},{"key":"2499_CR50","doi-asserted-by":"publisher","unstructured":"Gallaher, J., Hawkins-Daarud, A., Massey, S. C., Swanson, K., & Anderson, A. R. A. Hybrid approach for parameter estimation in agent-based models. bioRxiv https:\/\/doi.org\/10.1101\/175661 (2017).","DOI":"10.1101\/175661"},{"key":"2499_CR51","doi-asserted-by":"publisher","first-page":"20180943","DOI":"10.1098\/rsif.2018.0943","volume":"16","author":"D Warne","year":"2019","unstructured":"Warne, D., Baker, R. E. & Simpson, M. J. Simulation and inference algorithms for stochastic biochemical reaction networks: from basic concepts to state-of-the-art. J. R. Soc. Interface 16, 20180943 (2019).","journal-title":"J. R. Soc. Interface"},{"key":"2499_CR52","first-page":"106","volume":"10","author":"B Lambert","year":"2018","unstructured":"Lambert, B. et al. Bayesian inference of agent-based models: a tool for studying kidney branching morphogenesis. J. Math. Biol. 10, 106 (2018).","journal-title":"J. Math. Biol."},{"key":"2499_CR53","unstructured":"National Cancer Institute. Cancer Trends Progress Report. https:\/\/progressreport.cancer.gov\/. (2020)"},{"key":"2499_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"2499_CR55","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"G. O. Consortium.","year":"2019","unstructured":"G. O. Consortium. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 47, D330\u2013D338 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2499_CR56","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1101\/gad.14.15.1837","volume":"14","author":"P Polakis","year":"2000","unstructured":"Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837\u20131851 (2000).","journal-title":"Genes Dev."},{"key":"2499_CR57","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/\u03b2 -catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"key":"2499_CR58","first-page":"611","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Clin. Oncol."},{"key":"2499_CR59","doi-asserted-by":"publisher","first-page":"8358","DOI":"10.1073\/pnas.150152697","volume":"97","author":"E Labb\u00e9","year":"2000","unstructured":"Labb\u00e9, E., Letamendia, A. & Attisano, L. Association of smads with lymphoid enhancer binding factor 1\/t cell-specific factor mediates cooperative signaling by the transforming growth factor-\u03b2 and wnt pathways. Proc. Natl. Acad. Sci. USA 97, 8358\u20138363 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2499_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-04042-w","volume":"9","author":"V Murillo-Garz\u00f3n","year":"2018","unstructured":"Murillo-Garz\u00f3n, V. et al. Frizzled-8 integrates wnt-11 and transforming growth factor-\u03b2 signaling in prostate cancer. Nature Commun. 9, 1\u201316 (2018).","journal-title":"Nature Commun."},{"key":"2499_CR61","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1038\/onc.2017.144","volume":"36","author":"N Kramer","year":"2017","unstructured":"Kramer, N. et al. Autocrine wnt2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene 36, 5460\u20135472 (2017).","journal-title":"Oncogene"},{"key":"2499_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-316","volume":"13","author":"DT Bravo","year":"2013","unstructured":"Bravo, D. T. et al. Frizzled-8 receptor is activated by the wnt-2 ligand in non-small cell lung cancer. BMC Cancer 13, 316 (2013).","journal-title":"BMC Cancer"},{"key":"2499_CR63","doi-asserted-by":"publisher","first-page":"e57393","DOI":"10.1371\/journal.pone.0057393","volume":"8","author":"D Bartis","year":"2013","unstructured":"Bartis, D. et al. Down-regulation of canonical and up-regulation of non-canonical wnt signalling in the carcinogenic process of squamous cell lung carcinoma. PloS ONE 8, e57393 (2013).","journal-title":"PloS ONE"},{"key":"2499_CR64","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1371\/journal.pbio.0040115","volume":"4","author":"AJ Mikels","year":"2006","unstructured":"Mikels, A. J. & Nusse, R. Purified wnt5a protein activates or inhibits \u03b2 -catenin-tcf signaling depending on receptor context. PLoS Biol. 4, e115 (2006).","journal-title":"PLoS Biol."},{"key":"2499_CR65","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbamcr.2012.01.004","volume":"1823","author":"I Ahmad","year":"2012","unstructured":"Ahmad, I., Iwata, T. & Leung, H. Y. Mechanisms of fgfr-mediated carcinogenesis. Biochim. Biophys. Acta 1823, 850\u2013860 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"2499_CR66","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/sj.onc.1203186","volume":"18","author":"D Ricol","year":"1999","unstructured":"Ricol, D. et al. Tumour suppressive properties of fibroblast growth factor receptor 2-iiib in human bladder cancer. Oncogene 18, 7234\u20137243 (1999).","journal-title":"Oncogene"},{"key":"2499_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"JE Lee","year":"2019","unstructured":"Lee, J. E., Shin, S.-H., Shin, H.-W., Chun, Y.-S. & Park, J.-W. Nuclear fgfr2 negatively regulates hypoxia-induced cell invasion in prostate cancer by interacting with hif-1 and hif-2. Sci. Rep. 9, 1\u201312 (2019).","journal-title":"Sci. Rep."},{"key":"2499_CR68","doi-asserted-by":"publisher","first-page":"e63610","DOI":"10.1371\/journal.pone.0063610","volume":"8","author":"WW Lockwood","year":"2013","unstructured":"Lockwood, W. W., Chandel, S. K., Stewart, G. L., Erdjument-Bromage, H. & Beverly, L. J. The novel ubiquitin ligase complex, scffbxw4, interacts with the cop9 signalosome in an f-box dependent manner, is mutated, lost and under-expressed in human cancers. PloS ONE 8, e63610 (2013).","journal-title":"PloS ONE"},{"key":"2499_CR69","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1073\/pnas.0803379105","volume":"105","author":"A Dutt","year":"2008","unstructured":"Dutt, A. et al. Drug-sensitive fgfr2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. 105, 8713\u20138717 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2499_CR70","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1038\/onc.2013.427","volume":"33","author":"M Tamura","year":"2014","unstructured":"Tamura, M. et al. Forkhead transcription factor foxf1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness. Oncogene 33, 4837\u20134846 (2014).","journal-title":"Oncogene"},{"key":"2499_CR71","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1158\/0008-5472.CAN-10-1576","volume":"70","author":"P-K Lo","year":"2010","unstructured":"Lo, P.-K. et al. Epigenetic inactivation of the potential tumor suppressor gene foxf1 in breast cancer. Cancer Res. 70, 6047\u20136058 (2010).","journal-title":"Cancer Res."},{"key":"2499_CR72","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1126\/science.1197454","volume":"331","author":"Q Li","year":"2011","unstructured":"Li, Q. et al. The antiproliferative action of progesterone in uterine epithelium is mediated by hand2. Science 331, 912\u2013916 (2011).","journal-title":"Science"},{"key":"2499_CR73","doi-asserted-by":"publisher","first-page":"e1001551","DOI":"10.1371\/journal.pmed.1001551","volume":"10","author":"A Jones","year":"2013","unstructured":"Jones, A. et al. Role of dna methylation and epigenetic silencing of hand2 in endometrial cancer development. PLoS Med. 10, e1001551 (2013).","journal-title":"PLoS Med."},{"key":"2499_CR74","doi-asserted-by":"publisher","first-page":"86174","DOI":"10.18632\/oncotarget.13363","volume":"7","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Comprehensive analysis of aberrantly expressed profiles of lncrnas and mirnas with associated cerna network in muscle-invasive bladder cancer. Oncotarget 7, 86174 (2016).","journal-title":"Oncotarget"},{"key":"2499_CR75","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1101\/gad.225334.113","volume":"27","author":"JH Tsai","year":"2013","unstructured":"Tsai, J. H. & Yang, J. Epithelial\u2013mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192\u20132206 (2013).","journal-title":"Genes Dev."},{"key":"2499_CR76","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2016.01.009","volume":"164","author":"C David","year":"2016","unstructured":"David, C. et al. TGF-\u03b2 tumor suppression through a lethal EMT. Cell 164, 1015\u20131030 (2016).","journal-title":"Cell"},{"key":"2499_CR77","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori, N., Oristian, D. & Fuchs, E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963\u2013976 (2015).","journal-title":"Cell"},{"key":"2499_CR78","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611\u20131624 (2017).","journal-title":"Cell"},{"key":"2499_CR79","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrg2502","volume":"10","author":"G Gibson","year":"2009","unstructured":"Gibson, G. Decanalization and the origin of complex disease. Nat. Rev. Genet. 10, 134\u2013140 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"2499_CR80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/bjc.2017.171","volume":"117","author":"K Cyll","year":"2017","unstructured":"Cyll, K. et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br. J. Cancer 117, 367\u2013375 (2017).","journal-title":"Br. J. Cancer"},{"key":"2499_CR81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","volume":"14","author":"CJA Punt","year":"2017","unstructured":"Punt, C. J. A., Koopman, M. & Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 14, 235\u2013246 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2499_CR82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2499_CR83","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coisb.2018.02.009","volume":"9","author":"AL MacLean","year":"2018","unstructured":"MacLean, A. L., Hong, T. & Nie, Q. Exploring intermediate cell states through the lens of single cells. Curr. Opin. Syst. Biol. 9, 32\u201341 (2018).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"2499_CR84","doi-asserted-by":"publisher","first-page":"021001","DOI":"10.1088\/1478-3975\/aaf928","volume":"16","author":"Y Sha","year":"2019","unstructured":"Sha, Y. et al. Intermediate cell states in epithelial-to-mesenchymal transition. Physical Biol. 16, 021001 (2019).","journal-title":"Physical Biol."},{"key":"2499_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00401706.1991.10484804","volume":"33","author":"MD Morris","year":"1991","unstructured":"Morris, M. D. Factorial sampling plans for preliminary computational experiments. Technometrics 33, 161\u2013174 (1991).","journal-title":"Technometrics"},{"key":"2499_CR86","doi-asserted-by":"publisher","first-page":"7954","DOI":"10.3182\/20140824-6-ZA-1003.01968","volume":"47","author":"H Sohier","year":"2014","unstructured":"Sohier, H., Farges, J.-L. & Piet-Lahanier, H. Improvement of the representativity of the morris method for air-launch-to-orbit separation. IFAC Proceed. 47, 7954\u20137959 (2014).","journal-title":"IFAC Proceed."},{"key":"2499_CR87","doi-asserted-by":"crossref","unstructured":"de Pillis, L. G. & Radunskaya, A. E. Modeling tumor\u2013immune dynamics. In Mathematical Models of Tumor-Immune System Dynamics, pp. 59\u2013108 (Springer, 2014).","DOI":"10.1007\/978-1-4939-1793-8_4"},{"key":"2499_CR88","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113 (2013).","journal-title":"Nat. Genet."},{"key":"2499_CR89","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109\u20131112 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2499_CR90","doi-asserted-by":"publisher","first-page":"djv304","DOI":"10.1093\/jnci\/djv304","volume":"108","author":"I Jatoi","year":"2016","unstructured":"Jatoi, I. et al. Time-varying effects of breast cancer adjuvant systemic therapy. J. Natl. Cancer Inst. 108, djv304 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"2499_CR91","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (msigdb) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"2499_CR92","first-page":"1175","volume":"14","author":"J Vanhatalo","year":"2013","unstructured":"Vanhatalo, J. et al. GPstuff: bayesian modeling with gaussian processes. J. Mach Learn. Res. 14, 1175\u20131179 (2013).","journal-title":"J. Mach Learn. Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02499-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T16:09:15Z","timestamp":1675613355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-02499-y","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Min Yu is the founder and president of CanTraCer Biosciences Inc. and a consultant for Microsensor labs. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"983"}}